Thus, ACNs would be expected to have high levels of effective anti-NSCLC agents in binding to the α7nAChR-mediated signaling pathways, which may result in suppression of the receptor in a concentration-dependent manner. The gene discussed is CHRNA7; the disease is non-small cell lung carcinoma.